Modified Rapid Sequence Induction in Morbidly Obese Patients

Summary

This study investigates the effect of 4 different methods of rapid sequence induction (RSI) in morbidly obese patients on the amount of air insufflation into the stomach.

Conditions

• Anesthesia Intubation Complication

Interventions

PROCEDURE

Rapid sequence induction t-RSI

Preoxygenation via face mask, no ventilation with no PEEP until intubation

PROCEDURE

Rapid sequence induction m-RSI-PEEP

Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.

PROCEDURE

Rapid sequence induction m-RSI-vent

Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.

PROCEDURE

m-RSI-vent-cric

Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.

PROCEDURE

Cricoid Pressure

Cricoid Pressure will be applied during RSI until laryngoscopy

DRUG

Anesthetics

Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).

DIAGNOSTIC_TEST

Aspiration of gastric air via nasogastric tube

A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.

DIAGNOSTIC_TEST

Impression of gastric inflation at laparoscopy.

The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.

DIAGNOSTIC_TEST

Arterial blood gas

Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.

Sponsors & Collaborators

• Medical University of Vienna

  lead OTHER

Principal Investigators

• Walter Plöchl, Professor · Medical University of Vienna

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-02-28

Primary Completion

2021-02-28

Completion

2021-02-28

Countries

• Austria

Study Locations